Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years.

Xu-Ya Yu,Zhi-Ping Chen,Shen-Yu Wang,Hui-Rong Pan,Zhi-Fang Wang,Qiu-Fen Zhang,Ling-Zhi Shen, Xiao-Ping Zheng,Chuan-Fu Yan, Mei Lu,Bo Chen,Ya Zheng,Jun Zhang,Hua-Kun Lv,Shou-Jie Huang

Vaccine（2019）

引用 24|浏览43

暂无评分

摘要

•96.7% of the elderly people aged >65 y seroconverted at month 7.•Hecolin® was very well tolerated in elderly people aged >65 y.•No vaccine related SAE was reported.•This trial provided new data of the Hecolin® applied in elderly people aged >65 y.

查看译文

关键词

HEV,CI,PPS,GMC,AE,SAE,ELISA,WHO

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years.

Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years.